Home › Funds › Artia Global Partners LP › EWTX
Artia Global Partners LP position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
Artia Global Partners LP reported holding 98,800 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.0M, representing 0.74% of its reported portfolio and ranking #30 among its reported holdings. Artia Global Partners LP has disclosed EWTX holdings in 3 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's EWTX position evolved
Artia Global Partners LP first disclosed a stake in EWTX in Q4 2024 at 50,000 shares (US$1.3M). The position peaked in Q2 2026 at 98,800 shares, worth US$4.0M. Across 3 filings, Artia Global Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 98,800 shares valued at US$4.0M — an increase of 33,300 shares quarter over quarter.. Notable position changes include a 51% increase in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 50.00K | $1.33M | New |
| Q1 2026 | 65.50K | $2.06M | New |
| Q2 2026 | 98.80K | $4.01M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held EWTX?
Artia Global Partners LP has disclosed EWTX holdings in 3 of the last 7 reported quarters, going back to Q4 2024.
What is Artia Global Partners LP's current position in EWTX?
As of Q2 2026, Artia Global Partners LP holds 98.80K shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $4.01M, representing 0.74% of its reported portfolio and ranking #30.
Has Artia Global Partners LP been buying or selling EWTX?
In the latest 13F filing (Q2 2026), Artia Global Partners LP increased its position in EWTX. The position peaked in Q2 2026 at 98.80K shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.